कंपनी का अवलोकन
Verastem, Inc. operates as a development-stage biopharmaceutical entity dedicated to the creation and commercialization of pharmaceutical agents specifically designed for cancer treatment within the United States market. The company functions within the Healthcare sector and is classified under the Biotechnology industry, a classification that signifies an enterprise focused on innovative drug discovery and medical product development rather than established manufacturing or consumer services. As of the latest reporting period, the organization maintains a market capitalization of $478.70M, generates annual revenue of $30.91M, and employs a workforce of 102 individuals. These financial dimensions indicate that Verastem is a mid-sized entity in the biotechnology landscape, possessing significant cash reserves relative to its revenue but lacking the profitability scale typical of mature pharmaceutical firms. The valuation suggests the market is pricing the company based on potential future product approvals and clinical trial outcomes rather than current earnings power, which is characteristic of development-stage firms where capital allocation is directed toward research and development activities.
वित्तीय स्वास्थ्य
The company reported a total revenue of $30.91M over the trailing twelve months, yet simultaneously recorded a net income of $-209,471,008 and an EBITDA of $-169,400,992. The substantial discrepancy between the positive revenue figure and the deeply negative net income reveals a cost structure dominated by high research and development expenses, clinical trial costs, and general administrative overhead that significantly outpace current sales generation. Free cash flow stands at $-82,332,872, indicating that the company is burning cash to fund its operational activities, which limits immediate financial flexibility but is a necessary condition for asset accumulation in the biotechnology sector. The gross margin is reported at 85.1%, suggesting high efficiency in the cost of goods sold relative to revenue, while the operating margin of -236.5% and profit margin of 0.0% highlight the severe operating losses incurred before and after interest and taxes. On the balance sheet, the company holds $204.99M in cash against $87.17M in debt, resulting in a debt-to-equity ratio of 152.40, which indicates a leveraged position where debt obligations exceed equity capitalization. Despite the leverage, the current ratio of 3.09 demonstrates robust short-term liquidity, implying the firm possesses ample current assets to cover its short-term liabilities without immediate distress. Return on Equity stands at -1480.2% and Return on Assets at -61.1%, metrics that reveal management is currently generating substantial negative returns on the capital invested, a common but risky profile for companies in the pre-revenue or late-stage clinical phases.
मूल्यांकन आकलन
Valuation metrics for the company present a complex picture due to the lack of positive earnings, with the P/E Ratio (TTM) listed as N/A and the Forward P/E showing a negative value of -4.61. The negative forward P/E implies that the market is projecting earnings that would mathematically result in a negative multiple, reflecting the expectation that the company will likely remain unprofitable in the near term. The Price to Book ratio is 7.40, indicating that the market values the company at a significant premium over its book value, which often reflects the intrinsic value of intellectual property and potential pipeline assets not captured on the balance sheet. Alternatively, the Price to Sales ratio of 15.48 and an EV/EBITDA of -2.13 suggest the valuation is entirely driven by sales volume and sales-based multiples rather than profitability or earnings generation. The stock price has fluctuated between a 52-week high of $11.25 and a low of $4.01, and without a specific current price provided in the facts, the trading position relative to this range cannot be numerically calculated, though the range indicates a high volatility environment. The Beta of 0.43 suggests that the stock's price volatility is significantly lower than the broader market, moving less than half as much as the market index in typical conditions.
Growth & Income
The available data indicates N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), meaning that year-over-year growth rates cannot be calculated from the provided historical data points. In the absence of growth rate statistics, it is impossible to determine if earnings are growing faster or slower than revenue, as the necessary comparative data is not available in the source facts. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that the firm reinvests all available resources, including its substantial cash hoard, into research, development, and operational expansion rather than returning capital to shareholders. Consequently, the overall growth and income profile is defined by capital retention and reinvestment rather than dividend income or proven historical growth trajectories, presenting a high-risk, high-reward dynamic typical of development-stage biopharmaceutical companies.